# Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers

> **NCT03644095** · PHASE1 · COMPLETED · sponsor: **Reckitt Benckiser Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Mucinex® SE
- **DRUG:** Vicks Cough Syrup for Chesty Coughs

## Key facts

- **NCT ID:** NCT03644095
- **Lead sponsor:** Reckitt Benckiser Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-16
- **Primary completion:** 2009-02-01
- **Final completion:** 2009-02-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644095, "Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03644095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*